Werewolf Therapeutics, Inc.
HOWL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785530
In the last 90 days, Werewolf Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 45 institutions reported holding it in 13F filings for Q2 2026, worth $3.91M in total; no superinvestor holds it.
Q1 2022 vs. Q4 2021
How the institutions holding Werewolf Therapeutics, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Q1 2022 | Change |
|---|---|---|---|
| Holders | 51 | 49 | −2 |
| Shares | 19.1M | 19.0M | −120.8K (−0.6%) |
| Value | $228.3M | $83.5M | −$144.7M (−63.4%) |
New holders (6)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 42,401 | $187.0K | 0.00% |
| Citadel Advisors LLC | 20,144 | $89.0K | 0.00% |
| Barclays PLC | 4,287 | $19.0K | 0.00% |
| Amalgamated Bank | 3,946 | $17.0K | 0.00% |
| Amalgamated Financial Corp. | 3,946 | $17.0K | 0.00% |
| Oliver Lagore Vanvalin Investment Group | 580 | $3.00K | 0.00% |
Sold out (8)
Institutions that held Werewolf Therapeutics, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| Avidity Partners Management LP | 485,000 | $5.78M |
| Soleus Capital Management, L.P. | 64,585 | $769.0K |
| Manufacturers Life Insurance Company, The | 12,831 | $153.0K |
| Susquehanna International Group, LLP | 11,829 | $141.0K |
| MetLife Investment Management | 11,421 | $136.0K |
| Metropolitan Life Insurance Co | 8,460 | $100.8K |
| High Net Worth Advisory Group LLC | 500 | $6.00K |
| Confluence Wealth Services, Inc. | 100 | $1.00K |